The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for pathologic complete response (pCR) in the breast and axilla.
And also assess 3-year invasive disease-free survival (iDFS) in patients with HER2-positive (HER: human epidermal receptor) breast cancer treated with neoadjuvant trastuzumab and pertuzumab (± endocrine therapy) using a FDG-PET response-adapted strategy.
Protocol Amendment History
18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2017-05-18; most recent amendment 2025-04-22.
Status change: Completed → Active, Not Recruiting2024-02-02
Status change: Active, Not Recruiting → Completed2023-12-13
Status change: Recruiting → Active, Not Recruiting2019-08-28
Status change: Not Yet Recruiting → Recruiting2017-07-18